Bal Pharma Limited (BALPHARMA.BO)
INR 120.0
(-0.87%)
INR 120.0
(-0.87%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 770.19 Million INR | -40.04% |
| 2022 | 1.28 Billion INR | 14.82% |
| 2021 | 1.11 Billion INR | 18.73% |
| 2020 | 942.27 Million INR | 13.88% |
| 2019 | 827.4 Million INR | -17.51% |
| 2018 | 1 Billion INR | -3.17% |
| 2017 | 1.03 Billion INR | -3.35% |
| 2016 | 1.07 Billion INR | 20.38% |
| 2015 | 890.38 Million INR | 4.53% |
| 2014 | 851.77 Million INR | 1.84% |
| 2013 | 836.4 Million INR | 19.96% |
| 2012 | 697.25 Million INR | 10.88% |
| 2011 | 628.85 Million INR | 18.85% |
| 2010 | 529.11 Million INR | 14.47% |
| 2009 | 462.25 Million INR | -8.27% |
| 2008 | 503.91 Million INR | 17.56% |
| 2007 | 428.65 Million INR | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 179.45 Million INR | -22.21% |
| 2023 Q1 | 313.75 Million INR | -8.7% |
| 2023 Q2 | 392.28 Million INR | 25.03% |
| 2023 Q3 | 358.16 Million INR | -8.7% |
| 2023 Q4 | 230.68 Million INR | -35.59% |
| 2023 FY | 770.19 Million INR | -40.04% |
| 2022 FY | 1.28 Billion INR | 14.82% |
| 2022 Q4 | 343.66 Million INR | 8.28% |
| 2022 Q3 | 317.37 Million INR | -4.91% |
| 2022 Q2 | 333.75 Million INR | 16.24% |
| 2022 Q1 | 287.12 Million INR | 16.21% |
| 2021 Q4 | 247.06 Million INR | -15.0% |
| 2021 Q3 | 290.65 Million INR | -6.98% |
| 2021 Q2 | 312.46 Million INR | 25.26% |
| 2021 FY | 1.11 Billion INR | 18.73% |
| 2021 Q1 | 249.46 Million INR | 4.31% |
| 2020 Q2 | 232.51 Million INR | 3.31% |
| 2020 FY | 942.27 Million INR | 13.88% |
| 2020 Q3 | 260.46 Million INR | 12.02% |
| 2020 Q4 | 239.14 Million INR | -8.19% |
| 2020 Q1 | 225.06 Million INR | 62.31% |
| 2019 FY | 827.4 Million INR | -17.51% |
| 2019 Q2 | 240.42 Million INR | 2.11% |
| 2019 Q1 | 235.44 Million INR | 5.38% |
| 2019 Q3 | 206.16 Million INR | -14.25% |
| 2019 Q4 | 138.65 Million INR | -32.75% |
| 2018 Q4 | 223.42 Million INR | -5.44% |
| 2018 Q2 | 301.36 Million INR | 27.54% |
| 2018 FY | 1 Billion INR | -3.17% |
| 2018 Q1 | 236.28 Million INR | -25.87% |
| 2018 Q3 | 236.28 Million INR | -21.59% |
| 2017 FY | 1.03 Billion INR | -3.35% |
| 2017 Q4 | 318.75 Million INR | 0.0% |
| 2016 Q3 | 293.61 Million INR | -5.88% |
| 2016 FY | 1.07 Billion INR | 20.38% |
| 2016 Q4 | 335.16 Million INR | 14.15% |
| 2016 Q2 | 311.95 Million INR | 32.38% |
| 2016 Q1 | 235.65 Million INR | -2.02% |
| 2015 Q4 | 240.5 Million INR | -10.75% |
| 2015 FY | 890.38 Million INR | 4.53% |
| 2015 Q1 | 240.5 Million INR | -1.53% |
| 2015 Q2 | 256 Million INR | 6.44% |
| 2015 Q3 | 269.47 Million INR | 5.26% |
| 2014 Q1 | 205.57 Million INR | -7.44% |
| 2014 Q4 | 244.24 Million INR | 19.28% |
| 2014 Q3 | 204.75 Million INR | -8.98% |
| 2014 FY | 851.77 Million INR | 1.84% |
| 2014 Q2 | 224.95 Million INR | 9.43% |
| 2013 Q1 | 197.58 Million INR | 1.8% |
| 2013 Q4 | 222.09 Million INR | 7.09% |
| 2013 FY | 836.4 Million INR | 19.96% |
| 2013 Q2 | 209.33 Million INR | 5.95% |
| 2013 Q3 | 207.39 Million INR | -0.93% |
| 2012 Q2 | 168.39 Million INR | 9.3% |
| 2012 Q1 | 154.07 Million INR | -18.3% |
| 2012 Q3 | 173.13 Million INR | 2.81% |
| 2012 Q4 | 194.09 Million INR | 12.11% |
| 2012 FY | 697.25 Million INR | 10.88% |
| 2011 Q3 | 152.15 Million INR | -2.43% |
| 2011 Q4 | 188.57 Million INR | 23.94% |
| 2011 FY | 628.85 Million INR | 18.85% |
| 2011 Q2 | 155.94 Million INR | 0.0% |
| 2010 FY | 529.11 Million INR | 14.47% |
| 2009 FY | 462.25 Million INR | -8.27% |
| 2008 FY | 503.91 Million INR | 17.56% |
| 2007 FY | 428.65 Million INR | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Ajanta Pharma Limited | 21.06 Billion INR | 96.344% |
| Amrutanjan Health Care Limited | 1.55 Billion INR | 50.519% |
| Sigachi Industries Limited | 2 Billion INR | 61.534% |
| Ind-Swift Laboratories Limited | 6.19 Billion INR | 87.566% |
| Medico Remedies Limited | 262.14 Million INR | -193.806% |
| Lasa Supergenerics Limited | 121.02 Million INR | -536.367% |
| Venus Remedies Limited | 2.18 Billion INR | 64.712% |
| Sun Pharma Advanced Research Company Limited | -602.4 Million INR | 227.853% |
| Alpa Laboratories Limited | 188.89 Million INR | -307.737% |
| Nectar Lifesciences Limited | 2.97 Billion INR | 74.085% |
| Shilpa Medicare Limited | 3.54 Billion INR | 78.285% |
| Aarti Drugs Limited | 8.31 Billion INR | 90.739% |
| Lupin Limited | 123.71 Billion INR | 99.377% |
| Aurobindo Pharma Limited | 154.68 Billion INR | 99.502% |
| Zydus Lifesciences Limited | 125.21 Billion INR | 99.385% |
| Windlas Biotech Limited | 1.33 Billion INR | 42.471% |
| Suven Life Sciences Limited | -200.79 Million INR | 483.569% |
| Eris Lifesciences Limited | 10.42 Billion INR | 92.613% |
| Valiant Laboratories Limited | -60.66 Million INR | 1369.608% |
| J. B. Chemicals & Pharmaceuticals Limited | 22.69 Billion INR | 96.607% |
| Solara Active Pharma Sciences Limited | 861.2 Million INR | 10.567% |
| Ipca Laboratories Limited | 29.8 Billion INR | 97.416% |
| Bliss GVS Pharma Limited | 3.69 Billion INR | 79.158% |
| Achyut Healthcare Limited | 4.86 Million INR | -15744.374% |
| Sun Pharmaceutical Industries Limited | 258.48 Billion INR | 99.702% |
| Bajaj HealthCare Limited | 1.47 Billion INR | 47.67% |
| RPG Life Sciences Limited | 2.48 Billion INR | 68.981% |
| Mankind Pharma Limited | 44.52 Billion INR | 98.27% |
| Laurus Labs Limited | 24.62 Billion INR | 96.872% |
| Piramal Pharma Limited | 24.47 Billion INR | 96.853% |
| Syncom Formulations (India) Limited | 942.39 Million INR | 18.273% |
| Torrent Pharmaceuticals Limited | 46.75 Billion INR | 98.353% |
| Alembic Pharmaceuticals Limited | 26.78 Billion INR | 97.124% |
| Glenmark Pharmaceuticals Limited | 69.34 Billion INR | 98.889% |
| Unichem Laboratories Limited | 4.86 Billion INR | 84.168% |
| Sequent Scientific Limited | 2.97 Billion INR | 74.144% |
| Novartis India Limited | 1.32 Billion INR | 41.955% |
| Wanbury Limited | 1.73 Billion INR | 55.497% |
| Suven Pharmaceuticals Limited | 4.12 Billion INR | 81.321% |
| Wockhardt Limited | 16.24 Billion INR | 95.257% |
| Themis Medicare Limited | 1.5 Billion INR | 48.787% |
| Jagsonpal Pharmaceuticals Limited | 652.59 Million INR | -18.021% |
| Jubilant Pharmova Limited | 19.64 Billion INR | 96.079% |
| Glenmark Life Sciences Limited | 12.43 Billion INR | 93.805% |
| Dr. Reddy's Laboratories Limited | 163.6 Billion INR | 99.529% |
| Divi's Laboratories Limited | 32.44 Billion INR | 97.626% |
| NATCO Pharma Limited | 25.73 Billion INR | 97.007% |
| Gufic Biosciences Limited | 4.16 Billion INR | 81.52% |
| IOL Chemicals and Pharmaceuticals Limited | 4.58 Billion INR | 83.186% |
| Ind-Swift Limited | 2.17 Billion INR | 64.548% |
| Procter & Gamble Health Limited | 5.78 Billion INR | 86.678% |
| FDC Limited | 8.33 Billion INR | 90.759% |
| Krebs Biochemicals & Industries Limited | 192.72 Million INR | -299.63% |
| Granules India Limited | 16.79 Billion INR | 95.415% |
| Medicamen Biotech Limited | 495.49 Million INR | -55.44% |
| Alkem Laboratories Limited | 52.29 Billion INR | 98.527% |
| AstraZeneca Pharma India Limited | 6.22 Billion INR | 87.623% |
| Biofil Chemicals and Pharmaceuticals Limited | 14.57 Million INR | -5182.653% |
| Brooks Laboratories Limited | 65.62 Million INR | -1073.72% |
| Megasoft Limited | 342.07 Million INR | -125.156% |
| ZIM Laboratories Limited | 1.26 Billion INR | 39.206% |
| Strides Pharma Science Limited | 14.38 Billion INR | 94.647% |
| Neuland Laboratories Limited | 8.24 Billion INR | 90.662% |
| Morepen Laboratories Limited | 6.16 Billion INR | 87.499% |
| Hikal Limited | 3.14 Billion INR | 75.496% |
| Indoco Remedies Limited | 6.04 Billion INR | 87.251% |
| Aarti Pharmalabs Limited | 5.83 Billion INR | 86.792% |
| Kilitch Drugs (India) Limited | 620.47 Million INR | -24.13% |
| Mangalam Drugs & Organics Limited | 703.6 Million INR | -9.464% |
| Hester Biosciences Limited | 1.27 Billion INR | 39.529% |